Pfizer's chaotic year wraps up with plunging stock, grim guidance

Key PointsPfizer faced a challenging 2023, marked by a significant 41.84% decline in its stock value as revenue for COVID-19 drugs fell faster than expected. The company anticipates full-year 2024 revenue to fall within the range of $58.5 to$61.5 billion, disappointing investors and analysts.The company's focus on acquisitions is slowing, and Pfizer is returning its focus to dividend increases and share buybacks.5 stocks we like better than PfizerInvestors who own Pfizer Inc. NYSE: PFE may have expected 20 ...